BITR2101
Oncology (via TNFR2)
Phase IActive
Key Facts
Indication
Oncology (via TNFR2)
Phase
Phase I
Status
Active
About Boston Immune Technologies & Therapeutics
Boston Immune Technologies & Therapeutics is a private, preclinical-to-clinical stage biotech developing a novel class of TNFR superfamily antagonists called TrapMAbs. Its platform technology aims to trap receptor molecules in an inactive state, offering potential efficacy and safety advantages over conventional antibodies for targets previously considered challenging. The company's lead asset, BITR2101 targeting TNFR2 for oncology, is in Phase I, with a second program, BITT311 targeting CD40 for autoimmunity, in IND-enabling studies. BITT operates with a lean team and is positioned in the high-potential but competitive immuno-oncology and autoimmune therapy markets.
View full company profile